[1] Samsu N.Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment[J]. Biomed Res Int, 2021:1497449. [2] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志,2018,10(1):64-67. [3] 任秋月,常柏. 水陆二仙丹合抵挡汤加减治疗早期糖尿病肾病的前瞻性研究[J]. 西部中医药,2021,34(7):9-12. [4] 张佳华,宁洪悦,安丽萍,等. 基于GSK-3β/CREB信号通路探讨加味肾气丸减轻糖尿病小鼠肾间质纤维化的作用机制[J]. 中国试验方剂学杂志,2023,29(16):162-169. [5] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102(5s): s1-s127. [6] 中华医学会内分泌学分会. 中国成人糖尿病肾脏病临床诊断的专家共识. 糖尿病天地(临床)[J],2016,10(6):243-253. [7] 杨霓芝,刘旭生. 糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J]. 上海中医药杂志,2007,(7):7-8. [8] 郑筱萸. 中药新药临床研究指导原则[M]. 北京:中国医药科技出版社,2002:44-45. [9] 杨婉莹,李彩娟,刘欣,等. 糖尿病肾病发病机制、诊断、检查及治疗[J]. 黑龙江医学,2023,47(23):2935-2938. [10] Sahakyan G, Vejux A, Sahakyan N.The Role of oxidative stress-mediated inflammation in the development of T2DM-induced diabetic nephropathy: possible preventive action of tannins and other oligomeric polyphenols[J]. Molecules, 2022, 27(24). [11] An Y, Xu BT, Wan SR, et al.The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction[J]. Cardiovasc Diabetol, 2023, 22(1): 237. [12] Singh DK, Winocour P, Farrington K.Oxidative stress in early diabetic nephropathy: fueling the fire[J]. Nat Rev Endocrinol, 2011, 7(3):176-184. [13] 卢子怡. 基于数据挖掘探讨中医药治疗糖尿病肾病Ⅲ期、Ⅳ期蛋白尿的证治规律研究 [D]. 2023. [14] 马锋锋,范增慧. 糖尿病肾病中医病因病机研究进展[J]. 中国中医基础医学杂志,2022,28(8):1373-1377. [15] 郑秋含,潘志. 防治糖尿病肾病常见药对研究进展[J]. 河北中医,2023,45(6):1034-1037,1043. [16] 陈龙. 水陆二仙丹加减方治疗早期糖尿病肾病临床观察[J]. 中国医学创新,2017,14(34):111-114. [17] Cheng H, Harris RC.Renal endothelial dysfunction in diabetic nephropathy[J]. Cardiovasc Hematol Disord Drug Targets, 2014, 14(1): 22-33. |